ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.

Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

A new bedside air humidifier has given sleep disorder specialist Resmed a strong start to the financial year. The US and Australian-listed company's net profit grew ...

It starts with snoring and sleep apnoea but it extends to heart attacks, diabetes, impotence, occupational health, obstetrics and many other areas. Australian-based ResMed is the global leader in this ...

THE US and Australian-listed company's net profit grew three per cent in the three months to September to $US83.3 million, while revenue rose six per cent.